A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Phase 1 Recruiting
230 enrolled
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
Phase 1 Recruiting
186 enrolled
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Phase 1 Recruiting
225 enrolled
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
Phase 1 Recruiting
18 enrolled
Q702 for the Treatment of Patients With Hematologic Malignancies
Phase 1 Recruiting
46 enrolled
A Study of GLB-001 in Patients With Myeloid Malignancies
Phase 1 Recruiting
108 enrolled
Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)
Phase 1 Recruiting
44 enrolled
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
Phase 1 Recruiting
50 enrolled
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
Phase 1 Recruiting
10 enrolled
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
Phase 1 Recruiting
75 enrolled
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
Phase 1 Recruiting
24 enrolled
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Phase 1 Recruiting
100 enrolled